Newsroom | 3057 results

Sorted by: Latest

Telemedicine/Virtual Medicine
-

MedX Announces Proposed Non-Brokered Private Placement to Raise up to $2,500,000 and Stock Option Grants

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing to raise up to $2,500,000 by way of a Non-Brokered Private Placement of up to 33,333,334 Units at $0.075 per Unit (“Unit”). Each Unit will be comprised of One (1) fully paid common share and One-half (1/2) of a Share Purchase Warrant; each whole Share Purchase Warrants (“Warrant(s)”) will be exercisable to purchase One (1) further Common Share at the price...
-

內視鏡AI: AI Medical Service Inc.的胃部AI內視鏡診斷支援系統獲得泰國FDA監管核准

東京--(BUSINESS WIRE)--(美國商業資訊)-- 專注於內視鏡AI診斷技術研發的醫療初創企業AI MEDICAL SERVICE INC.(以下簡稱「AIM」)欣然宣布,已於2025年6月26日獲得泰國食品藥物管理局(泰國FDA)的醫療器材核准。此次獲准的是該公司的內視鏡影像診斷支援軟體「gastroAI-model G」。該系統利用人工智慧技術,輔助醫生在內視鏡影像中區分腫瘤性與非腫瘤性胃部病變。這代表泰國第一個具備病變區分1能力的上消化道AI診斷支援系統獲得監管核准2。 我們在泰國完成監管審查與器材註冊工作的背景情況 胃癌是全球第五大常見癌症,每年新增病例超過100萬,死亡人數約60萬3。胃癌的特點是,其死亡率會隨著病情的進展而顯著上升。然而,胃癌若能在早期被發現,往往是可以治療的;第一期胃癌病患的5年相對生存率約為95%,而第三期及以後病患的生存率不足50%4。儘管如此,早期胃癌難以檢測,據統計,其漏診率高達4.5%至25.8%5。 在泰國,胃癌死亡率居高不下(約75%6的確診病患死於該疾病),這顯示許多病例在確診時已處於晚期。這一醫療挑戰還因顯著的人口結構趨勢而加...
-

内窥镜AI: AI Medical Service Inc.基于AI的胃部内窥镜诊断支持系统获得泰国FDA监管批准

东京--(BUSINESS WIRE)--(美国商业资讯)-- 专注于内窥镜AI诊断技术研发的医疗初创企业AI MEDICAL SERVICE INC.(以下简称“AIM”)欣然宣布,已于2025年6月26日获得泰国食品药品管理局(泰国FDA)的医疗器械批准。此次获批的是该公司的内窥镜影像诊断支持软件“gastroAI-model G”。该系统利用人工智能技术,辅助医生在内窥镜影像中区分肿瘤性与非肿瘤性胃部病变。这标志着泰国首个具备病变区分1能力的上消化道AI诊断支持系统获得监管批准2。 我们在泰国完成监管审查与器械注册工作的背景情况 胃癌是全球第五大常见癌症,每年新增病例超过100万,死亡人数约60万3。胃癌的特点是,其死亡率会随着病情的进展而显著上升。然而,胃癌若能在早期被发现,往往是可以治疗的;Ⅰ期胃癌患者的5年相对生存率约为95%,而Ⅲ期及以后患者的生存率不足50%4。尽管如此,早期胃癌难以检测,据统计,其漏诊率高达4.5%至25.85。 在泰国,胃癌死亡率居高不下(约75%6的确诊患者死于该疾病),这表明许多病例在确诊时已处于晚期。这一医疗挑战还因显著的人口结构趋势而加剧:作...
-

BetterRX Receives Strategic Investment from BVP Forge to Transform Hospice Pharmacy Care Nationwide and Appoints Tim Tannert as CEO

SALT LAKE CITY--(BUSINESS WIRE)--BetterRX, the leading hospice pharmacy platform, today announced a strategic growth investment from BVP Forge, to accelerate its future growth. BetterRX also announced the appointment of Tim Tannert as its new CEO. The investment will support BetterRX’s mission to end needless suffering caused by medication delays by expanding its platform reach, accelerating innovation, and advancing the standard of care in hospice medication management. Purpose-built for hospi...
-

Endoscopic AI: AI Medical Service Inc. Has Obtained Regulatory Approval from Thailand’s FDA for Its Gastric AI-based Endoscopic Diagnosis Support System

TOKYO--(BUSINESS WIRE)--AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce that it has received medical device approval from the Thai Food and Drug Administration (Thai FDA) on June 26, 2025. The approval is for its endoscopic image diagnosis support software, the "gastroAI-model G." This system utilizes artificial intelligence to assist physicians in differentiating between neoplastic and non-neoplas...
-

AIメディカルサービス:【内視鏡AI】タイにおける胃がん診断支援AIの認可を取得

東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 内視鏡の画像診断支援AI(人工知能)を開発する株式会社AIメディカルサービス(本社:東京都豊島区、代表取締役 多田 智裕、瀧川 泰司、以下「AIM」)は、2025年6月26日にAIを活用した胃病変の腫瘍性・非腫瘍性を判定する内視鏡画像診断支援システム(販売名:Endoscopic image diagnosis support software - gastroAI-model G)について、タイ保健省食品医薬品局(Thai Food and Drug Administration、以下「タイFDA」)から医療機器として認可されたことをご報告します。なお、タイにおける鑑別1機能を備えた上部消化管領域の診断支援AIの認可取得事例として初2となります。 ■タイにおける薬事認証取得を目指した背景 胃がんは世界で年間約100万人が罹患し、死亡者数は約60万人で、がん死亡者数の第5位に位置しています3。胃がんは早期に発見すれば十分に治療可能な疾患である一方、ステージが進行するにつれて生存率が大きく下がることが特徴で、5年相対生...
-

Atlas Home Health Brings Local Roots and National Expertise to Northern California

NAPA, Calif.--(BUSINESS WIRE)--Atlas Home Health is proud to announce its official launch, delivering private client home healthcare services for adults and children across Northern California. Founded by longtime healthcare leaders and Napa locals, Aaron Starfire, JD, and Robert Okin, MD, the company is committed to redefining excellence in home care. Starfire brings extensive expertise in home care delivery and health care navigation, while Dr. Okin is a nationally recognized leader in mental...
-

Heritage Group Closes on $370 Million Fourth Fund

NASHVILLE, Tenn.--(BUSINESS WIRE)--Heritage Group, a healthcare-focused private equity firm, today announced the final closing of Heritage Healthcare Innovation Fund IV (“Fund IV” or the “Fund”) at over $370 million, marking another significant milestone in the firm’s continued growth. Fund IV builds on Heritage Group’s successful strategy of making minority and majority investments in solution-oriented, high-growth healthcare services and technology businesses that address the industry’s most...
-

Reimagine Care Appoints Ann Stadjuhar as Chief Growth Officer to Accelerate Access to Innovative Cancer Care Solutions

NASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care, the nation’s leading provider of technology-enabled cancer care at home, today announced the appointment of Ann Stadjuhar as Chief Growth Officer. A seasoned healthcare executive with a track record of building and scaling high-growth digital health organizations, Stadjuhar will lead Reimagine Care’s growth, go-to-market strategy and partnership efforts to accelerate access to more convenient, connected cancer care for patients across the count...
-

DocGo to Announce Second Quarter 2025 Results on Thursday, August 7, 2025

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, announced today that the Company will release its financial results for the second quarter ended June 30, 2025 after the markets close on Thursday, August 7, 2025. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Thursday, August 7, 2025 5:...